DEF 14A: Exelixis Aims to Boost Shareholder Value with Strategic R&D Focus and $1 Billion Buyback Program

Exelixis is focused on improving cancer care and creating shareholder value through strategic R&D investments and a $1 billion share repurchase program.

Summary

• Exelixis is dedicated to improving cancer treatment standards through innovative drug development.
• In 2023, the company's oncology franchise, driven by cabozantinib, generated $1.8 billion in revenue, a 14% year-over-year increase, marking the seventh consecutive year of operating profit.
• The company is progressing its pipeline with new pivotal trials and promising clinical results, while also adding a new clinical-stage program.
• The Board of Directors has appointed five new independent directors since May 2023, bringing expertise in drug development, corporate governance, and finance.
• Exelixis plans to return $1 billion to stockholders through share repurchase programs (SRPs) by the end of 2024, with $550 million already returned in 2023 and an additional $450 million authorized for 2024.
• A corporate restructuring in January 2024 aims to focus R&D resources on clinical-stage activities and improve operational efficiency.
• Exelixis published its second Corporate Values & Sustainability Report in 2023, updating on environmental, social, and governance themes.
• The company updated its clawback policy and increased the CEO's stock ownership guidelines to six times his annual base salary.
• The 2024 Annual Meeting of Stockholders will be held virtually on May 30, 2024.
• Stockholders are being asked to vote on the election of directors, ratification of the independent auditor, amendment of the employee stock purchase plan, and executive compensation.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Exelixis, highlighting strong financial performance, strategic R&D focus, and commitment to shareholder value. The addition of experienced directors and the ongoing share repurchase program further contribute to the positive sentiment.

Positives

• Strong commercial performance of cabozantinib leading to significant revenue.
• Commitment to returning value to stockholders through share repurchase programs.
• Addition of experienced independent directors to the Board.
• Focus on R&D and pipeline development.
• Enhancement of corporate governance elements.

Negatives

• Departure of two directors, Alan M. Garber and Jacqueline Wright, reducing the Board size from thirteen to eleven.
• Termination of XL102 development program in December 2023.
• Did not meet enrollment targets for STELLAR-304 pivotal trial.
• Did not complete three transactions for oncology assets that are at or near clinical stage.

Risks

• Market acceptance of CABOMETYX and other Exelixis products.
• Effectiveness of CABOMETYX and other Exelixis products compared to competing products.
• Costs associated with commercialization, research and development, in-licensing or acquisition of product candidates.
• Potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates to demonstrate safety and/or efficacy in clinical testing.
• Dependence on relationships with collaboration partners.
• Complexities and unpredictability of regulatory review and approval processes.
• Continuing compliance with applicable legal and regulatory requirements.
• Unexpected concerns arising from adverse safety events or additional data analyses.
• Dependence on third-party vendors for development, manufacture and supply.
• Ability to protect intellectual property rights.
• Market competition, including potential for generic versions of Exelixis marketed products.
• Changes in economic and business conditions.

Future Outlook

Exelixis anticipates the next analysis of OS from CONTACT-02 in 2024 and plans to advance six DCs towards IND submissions between 2024 and 2026.

Management Comments

• Our objective is to create value for our shareholders.
• We can accomplish this by having a singular focus: to improve the standards of care for cancer patients through the discovery, development and introduction of new products with firstin-class or clinical best-in-class potential.
• The company recognizes that clinical differentiation drives commercial success, and with it, the creation of value for all of Exelixis stakeholders.
• Your Board of Directors is committed to improving outcomes for patients, as well as responsible stewardship and responsiveness to shareholder feedback and concerns.
• As it moves through 2024, Exelixis has a healthy balance sheet and strong commercial franchise, and is only just beginning to unlock the potential of its diverse, rapidly maturing pipeline.
• Simply put, there is much to look forward to.

Industry Context

Exelixis operates in the competitive biopharmaceutical industry, focusing on oncology. The company's success depends on its ability to innovate and commercialize new treatments, as well as maintain strong relationships with collaboration partners.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards in terms of financial metrics or R&D productivity.
• However, it mentions that the compensation program for non-employee directors is intended to be competitive and fair, benchmarking against a peer group.
• The company also benchmarks executive compensation against a peer group of 18 publicly-traded, U.S.-based biotechnology/pharmaceutical companies.

Management Changes

Corporate Governance

Related Party Transactions

• BlackRock, Inc., a greater than 5% holder of our common stock, managed a portion of our cash and investments portfolio. We incurred $0.4 million in fees for BlackRock advisory services performed during the year ended December 29, 2023.

Stakeholder Impact

• Shareholders: Potential for increased value through strategic R&D and share repurchase programs.
• Patients: Commitment to improving cancer care through innovative treatments.
• Employees: Opportunities for professional development and participation in the company's success through equity plans.
• Communities: Engagement and advocacy for improved cancer care and awareness.

Next Steps

• Conduct the 2024 Annual Meeting of Stockholders on May 30, 2024.
• Continue to progress the clinical development of cabozantinib and zanzalintinib.
• Advance six development candidates towards IND submissions between 2024 and 2026.
• Execute the $450 million share repurchase program for 2024.
• Monitor and manage risks associated with the business and operational activities.

Key Dates

Keywords

Exelixis, cabozantinib, oncology, share repurchase program, clinical trials, directors, corporate governance, R&D, zanzalintinib, pipeline